Sareum Share News (SAR)

Sareum Information

Buy SAR Shares
Add SAR to Watchlist
Add SAR to Alert

Share Price Information for Sareum (SAR)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 24.25

Bid: 24.00

Ask: 24.50

Change: -1.00 (-3.96%)

Spread: 0.50 (2.083%)

Open: 25.25

High: 25.25

Low: 24.25

Prev. Close: 25.25

Last checked at -

Small caps round-up: ProStrakan, Sareum,Sirius

Tue, 06th Oct 2009 09:47

Speciality pharmaceutical company ProStrakan's New Drug Application (NDA) filing for Abstral has been accepted for review by the US Food and Drug Administration (FDA). Subject to successful completion of the US approval process, the Scottish firm plans to launch Abstral, which helps ease pain for cancer patients, in the second half of 2010 in the US. Meanwhile, cancer drug discovery specialist Sareum says its joint research collaboration with The Institute of Cancer Research has made "excellent progress".Data shows how the novel Chk1 inhibitor SAR-020106, developed by the pair, can produce up to two-fold increases in the efficacy of marketed cancer chemotherapeutics.A bullish update has helped Germany-focused property investment group, Sirius Real Estate, improve Tuesday. It said 45,283 sqm of new leases were signed in the six months to 30 Spetember, with an average rent of €5.20 per square metre, compared to 55,900sqm signed at €4.50 psm for the full year to 31 March 2009."Although the environment for real estate companies remains challenging, the resilience of the Sirius model is apparent as our transformation process is enabling us to achieve substantially higher rents,' said chief executive Kevin Oppenheim.Bio-analytical technology Avacta has won a second order for its flagship Optim product from the biopharmaceutical sector.'Optim has been received by potential customers enthusiastically as a unique tool that will allow them to characterize their drug compounds at an early stage of development and provide information that will help reduce the risk of product development and ultimately reduce the cost to patients of these new drugs,' claimed Avacta's chief executive, Alastair Smith.Critical components maker Avingtrans has won a £1.25m order from Balfour Beatty for 30 large verge mounted poles to be used on the M4 motorway. First delivery of the poles will take place before Christmas.BioEnergy Africa is abandoning plans to produce ethanol from sugar cane in southern Africa and has ceased investment in the Massingir project in Mozambique. The company believes it would be unable in the current economic environment to get the $510m of financial backing required under the Massingir investment Agreement.Instead, the company will focus on investing in early stage exploration and development projects in the mining sector in sub-Saharan Africa. To reflect this the company will change its name to Sable Mining Africa.

More News

7 Dec 2023 14:31

UK shareholder meetings calendar - next 7 days

Friday 8 December
Amedeo Air Four Plus Ltd	AGM
Ashoka India Equity Investment Trust PLC	AGM
Associated British Engineering PLC	AGM
Associated British Foods PLC	AGM
Corcel PLC	GM re disposal of 41% interest in the Mambare nickel/cobalt project
Hargreaves Lansdown PLC	AGM
URA Holdings PLC	GM re closing the fundraise
Monday 11 December
IamFire PLC	AGM with vote on name change to WeCap PLC
Pharma C Investments PLC	GM re allowing investments in fintech, AI sectors
SigmaRoc PLC	GM re reverse takeover
Tribal Group PLC	GM re cash offer by Tiger Bidco 1 Ltd
Vela Technologies PLC	AGM
Tuesday 12 December
Atalaya Mining PLC	EGM re redomiciliation to Spain from Cyprus
Blackrock Greater Europe Investment Trust PLC	AGM
Distil PLC	GM re placing and subscription
Gelion PLC	AGM
Wednesday 13 December
Dechra Pharmaceuticals PLC	AGM
Limitless Earth PLC	AGM
Softcat PLC	AGM
Volution Group PLC	AGM
Thursday 14 December
Aeorema Communications PLC	AGM
CleanTech Lithium PLC	GM re equity raise approval
Driver Group PLC	Full Year Results
eEnergy Group PLC	AGM
Ethernity Networks Ltd	GM re authority to allot shares on non-preemptive basis
Fintech Asia Ltd	AGM
Helium One Global Ltd	AGM
Marwyn Value Investors Ltd	AGM
Quarto Group Inc	GM re cancelling trading on London's Main Market
Sareum Holdings PLC	AGM

Copyright 2023 Alliance News Ltd. All Rights Reserved.

23 Nov 2023 14:28

IN BRIEF: Sareum Holdings draws down on equity prepayment facility

Sareum Holdings PLC - Cambridge, England-based pharmaceutical company, focused on developing kinase inhibitors to treat autoimmune diseases and cancer - Says that it has drawn down on the GBP300,000 second deposit in respect of a previously announced equity prepayment facility.

9 Nov 2023 13:47

EARNINGS AND TRADING: MetalNRG hails Gold Ridge findings

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

3 Nov 2023 13:59

Sareum secures Japan patent for kinase inhibitor asset

(Sharecast News) - Biotechnology firm Sareum announced on Friday that it has received a notice of allowance from the Japan Patent Office for a patent associated with SDC-1801, its primary TYK2/JAK1 kinase inhibitor.

3 Nov 2023 09:01

Sareum says patent notice in Japan boosts confidence in SDC-1801

(Alliance News) - Sareum Holdings PLC on Friday said it received a notice of allowance from Japan's Patent Office for a patent relating to its lead TYK2/JAK1 kinase inhibitor, SDC-1801.

9 Oct 2023 15:06

Sareum losses widen as clinical trials continue

(Sharecast News) - Biotechnology company Sareum Holdings reported a loss of £3.2m after tax in its final results on Monday, widening from last year's £2.2m due to heightened expenses from initiating clinical studies with SDC-1801, despite aligning with market anticipations.

9 Oct 2023 10:58

Sareum says earnings down but product development going well

(Alliance News) - Sareum Holdings PLC on Monday said its annual loss widened and its cash reserves are substantially reduced, but that development and testing of its medicinal products is progressing well.

6 Sep 2023 14:35

Director dealings: Blackbird, Sareum insiders pick up shares

(Sharecast News) - Blackbird found itself with a number of entries on the list of director buys on Wednesday, after a number of insiders and associates bought shares.

4 Sep 2023 09:18

Sareum begins dosing participants in phase 1a trial for SDC-1801

(Alliance News) - Sareum Holdings PLC on Monday said it has successfully started the multiple ascending dose part of its phase 1a clinical trial for its SDC-1801 drug, following approval from the safety review committee.

16 Aug 2023 13:13

Sareum flagship drug trial progressing well ahead of annual results

(Alliance News) - Sareum Holdings PLC on Wednesday said a clinical trial for its main therapeutic is continuing as planned, and it hopes to use a new prepayment facility to further enhance development.

3 Aug 2023 14:16

IN BRIEF: Sareum secures GBP5 million of funding from RiverFort Global

Sareum Holdings PLC - Cambridge-based biotechnology company developing kinase inhibitors for autoimmune diseases and cancers - Agrees terms on equity prepayment facility of up to GBP5 million with RiverFort Global Opportunities PCC Ltd, as arranged by RiverFort Global Capital Ltd, with an initial deposit of GBP2 million. This is expected on August 4, net of associated costs.

26 Jun 2023 17:33

TRADING UPDATES: New patents for Sareum; Guanajuato hails assessment

(Alliance News) - The following is a round-up of updates by London-listed companies, issued Monday and not separately reported by Alliance News:

26 Jun 2023 10:54

Sareum granted new patents in China, US

(Sharecast News) - Clinical-stage biotechnology developer Sareum announced the granting of patents for its lead kinase inhibitors in China and the United States on Monday.

6 Jun 2023 13:36

IN BRIEF: Sareum doses first subjects in psoriasis drug trial

Sareum Holdings PLC - Cambridge-based biotechnology company developing kinase inhibitors for autoimmune diseases and cancers - Announces successful dosing of first test subjects in a randomised, placebo-controlled phase 1a clinical trial for lead programme SDC-1801. SDC-1801 is a dual TYK2/JAK1 kinase inhibitor and potential new therapeutic for various autoimmune diseases with an initial focus on psoriasis. The phase 1a trial will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of SDC-1801 in healthy subjects, in single and multiple ascending oral dose studies. Dosing has started in a specialist clinical unit in Melbourne, Australia. Sareum expects full safety data to become available during the first half of 2024, after which a phase 1b clinical study will commence post-haste if the Phase 1a trial obtains satisfactory results.

18 May 2023 14:31

TRADING UPDATES: Nuformix says NXP002 shows anti-inflammatory effect

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Latest Share Chat

Sareum Share News (SAR)

Share Price Information for Sareum (SAR)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: ProStrakan, Sareum,Sirius

Login to your account

Quickpicks are a member only feature

Login to your account